28
Participants
Start Date
October 31, 2003
Study Completion Date
May 31, 2005
Ziprasidone
IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
Pfizer Investigational Site, Mexico City
Pfizer Investigational Site, Mexico D F
Pfizer Investigational Site, DF
Pfizer Investigational Site, Monterrey
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY